Research and Markets (http://www.researchandmarkets.com/research/881581/commercial_insight) has announced the addition of the "Commercial Insight: Antidepressants - Novel Mechanism Offers Hope in Depressed Market" report to their offering.
With current blockbuster brands facing generic competition, Datamonitor forecasts the antidepressant market to decline at a compound annual growth rate of -2.0% between 2008 and 2018. However, an antidepressant with a novel mechanism of action has huge commercial potential and the most promising candidate to date is Servier and Novartis's melatonin agonist and serotonin antagonist Valdoxan (agomelatine).
Scope
- In-depth analysis of the current and future antidepressant drug class market across the US, Japan, France, Germany, Italy, Spain and the UK.
- Country-specific total brand sales forecasts for key products, generics and pipeline agents across the seven major markets to 2018.
- Assessment and appreciation of the numerous opportunities and threats present in the antidepressant market, with analysis of emerging markets trends.
- Case study evaluation of the strategies employed by key players in the antidepressant drug class market, including Wyeth, Forest, and Lundbeck.
Highlights of this title
Japan will remain a key growth market for antidepressant sales, shown through the launch of Remeron (mirtazapine; Schering Plough), Lexapro (escitalopram; Lundbeck and Mochida), Cymbalta (duloxetine; Eli Lilly and Shionogi) and Pristiq (desvenlafaxine; Wyeth).